So thank you, everyone, for joining us in the room and online at TD Cowen's 46th Annual Healthcare Conference. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And it is ...
Q4 revenue -- $67.3 million reported for the quarter ended Dec. 31, 2025, compared to $1.5 million in Q4 2024; increase driven primarily by AstraZeneca and Gilead (NASDAQ:GILD) payments. Full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results